Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma

Alex Holmes, Christine Kilpatrick, Joseph Proietto, Michael D. Green*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A 69-year-old woman with classic glucagonoma syndrome had associated progressive neurologic disease manifest as dementia, ataxia, optic atrophy, and lower limb weakness. Visual evoked responses (VERs) were absent bilaterally. After an attempt at resection was unsuccessful, therapy was started with somatostatin analogue (Sandostatin, SMS 201-995). Over the ensuing 3 months, there was a decrease in the plasma glucagon level, resolution of the rash, weight gain, reversal of the dementia, and an improvement in coordination and limb weakness. Subsequent VERs revealed bilateral delayed responses.

Original languageEnglish
Pages (from-to)434-436
Number of pages3
JournalAmerican Journal of Medicine
Volume91
Issue number4
DOIs
StatePublished - Oct 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma'. Together they form a unique fingerprint.

Cite this